Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH 45267; Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH 45267.
Semin Arthritis Rheum. 2017 Aug;47(1):143-148. doi: 10.1016/j.semarthrit.2017.02.004. Epub 2017 Feb 10.
To assess the clinical features, diagnosis, and treatment of bone sarcoidosis in the United States.
Patients with bone sarcoidosis were identified and matched to sarcoidosis patients based on race, gender, and age. Detailed characteristics were obtained by medical record review.
A total of 64 patients with bone sarcoidosis were enrolled in this study. The female:male ratio was 1.46:1 and the white:black ratio was 3:1. Thirty-eight (59.4%) of 64 patients had bone symptoms. Compared to matched cases, bone sarcoidosis patients have more multi-organ involvement and higher incidence with liver, spleen, and extrathoracic lymph node involvement than controls (P < 0.05). Spine was the most commonly affected bone in 44 (68.8%) of patients, followed by pelvis (35.9%), and hands (15.6%). MRI and PET/CT scan was the common imaging technology, which performed in 36 patients and 32 patients, respectively, and with 97.2% and 93.8% positive bone uptake. Laboratory test indicated anemia was more common in bone sarcoidosis group than controls (P = 0.044). Infliximab was more commonly used in bone sarcoidosis patients than controls (P = 0.009).
Bone sarcoidosis was associated with multi-organs affection, and high frequency of liver, spleen, or extrathoracic lymph node involvement. Infliximab should be considered in those patients with aggressive and refractory bone sarcoidosis.
评估美国骨骼类肉瘤病的临床特征、诊断和治疗方法。
通过病历回顾,确定并匹配骨骼类肉瘤病患者和类肉瘤病患者,匹配因素包括种族、性别和年龄。
本研究共纳入 64 例骨骼类肉瘤病患者。男女比例为 1.46:1,白种人:黑种人比例为 3:1。64 例患者中有 38 例(59.4%)有骨骼症状。与匹配病例相比,骨骼类肉瘤病患者多器官受累,肝、脾和胸外淋巴结受累的发生率高于对照组(P < 0.05)。44 例(68.8%)患者最常受累的骨骼是脊柱,其次是骨盆(35.9%)和手部(15.6%)。MRI 和 PET/CT 扫描是常见的影像学技术,分别在 36 例和 32 例患者中进行,阳性骨骼摄取率分别为 97.2%和 93.8%。实验室检查表明,骨骼类肉瘤病组贫血发生率高于对照组(P = 0.044)。与对照组相比,骨骼类肉瘤病患者更常使用英夫利昔单抗(P = 0.009)。
骨骼类肉瘤病常与多器官受累相关,且肝、脾或胸外淋巴结受累的频率较高。对于侵袭性和难治性骨骼类肉瘤病患者,应考虑使用英夫利昔单抗。